Novo Nordisk A/S: Share repurchase programme
Bagsværd, Denmark, 23 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 1 February 2018.
Under the programme initiated 5 February 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 6 February 2018 to 30 April 2018.
Since the announcement as of 16 April 2018, the following transactions have been made under the programme:
| Number of
B shares |
Average
purchase price |
Transaction
value, DKK |
|
| Accumulated, last announcement | 6,844,937 | 2,087,422,236 | |
| 16 April 2018 | 140,000 | 299.73 | 41,962,804 |
| 17 April 2018 | 140,000 | 295.99 | 41,438,693 |
| 18 April 2018 | 112,600 | 293.13 | 33,006,422 |
| 19 April 2018 | 150,000 | 290.08 | 43,511,804 |
| 20 April 2018 | 160,000 | 286.19 | 45,790,344 |
| Accumulated under the programme | 7,547,537 | 2,293,132,303 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 70,609,773 B shares of DKK 0.20, corresponding to 2.8% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 1 February 2018. As of 20 April 2018, Novo Nordisk has repurchased a total of 10,634,947 B shares at an average share price of DKK 305.30 per B share equal to a transaction value of DKK 3,246,833,252.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
| Christina Kjær | +45 3079 3009 | cnje@novonordisk.com |
Company announcement No 33 / 2018
Attachment